Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bacteria in Your Nose Could Produce New Antibiotics

By Ryan Bushey | July 29, 2016

The threat of antibiotic-resistant superbugs could be quashed due to a bacteria-fighting compound residing in our noses, called lugdunin.

A team of German scientists from the University of Tuebingen found this substance was produced by Staphylococcus lugdunensis (S. lugdunensis), a bacterium that resides in the nostrils, reported Reuters.

Lead researcher Andreas Peschel told reporters during a phone briefing that his team examined the nasal cavity because it houses a diverse ecosystem of an estimated 50 different species of bacterial, and serves as a focal point for the start of many viral infections.

Please follow R&D Magazine on LinkedIn

Experiments with lugdunin were conducted in two parts. The first focused on mice where the results showed the compound was able to successfully stave off a skin infection induced by Staphylococcus aureus (S. aureus) as well as certain strains of methicillin-resistant Staphylococcus aureus (MRSA), according to Reuters.

Next, the scientists studied nasal swabs from 187 hospital patients. Only 5.9 percent of the patient samples who had the lugdunensis bacterium living in their noses also hosted S. aureus indicating these microbes were keeping their infectious brethren at bay. By contrast, 34.7 percent of participants were found to have S. aureus in their noses with no traces of lugdunensis.

This research is in its very early stages, but it does highlight the potential for microbiome research as an R&D tool for new drugs, wrote Fortune. Previous efforts have focused on using gut bacteria living in the stomach as a future disease treatment. Lugdunin could mean the human body hosts another set of beneficial microorganisms.

The study was published in the journal Nature.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE